GenSight Biologics S.A
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more
GenSight Biologics S.A (GSGTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.098x
Based on the latest financial reports, GenSight Biologics S.A (GSGTF) has a cash flow conversion efficiency ratio of 0.098x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.15 Million) by net assets ($-32.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GenSight Biologics S.A - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how GenSight Biologics S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GenSight Biologics S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenSight Biologics S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyungkuk F&B Co Ltd
KQ:189980
|
0.069x |
|
ACARIX AB
F:7AC
|
N/A |
|
GWR Group Ltd
AU:GWR
|
0.020x |
|
Konya Kagit Sanayi ve Ticaret AS
IS:KONKA
|
-0.023x |
|
Awea Mechantronic Co Ltd
TW:1530
|
0.014x |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
0.049x |
|
Manolete Partners Plc
PINK:MANOF
|
0.081x |
|
Arrow Greentech Limited
NSE:ARROWGREEN
|
0.209x |
Annual Cash Flow Conversion Efficiency for GenSight Biologics S.A (2013–2024)
The table below shows the annual cash flow conversion efficiency of GenSight Biologics S.A from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-26.92 Million | $-12.94 Million | 0.481x | -40.18% |
| 2023-12-31 | $-30.70 Million | $-24.66 Million | 0.803x | -63.64% |
| 2022-12-31 | $-15.28 Million | $-33.75 Million | 2.209x | +306.10% |
| 2021-12-31 | $15.99 Million | $-17.14 Million | -1.072x | +16.87% |
| 2020-12-31 | $11.67 Million | $-15.04 Million | -1.289x | +46.12% |
| 2019-12-31 | $11.75 Million | $-28.11 Million | -2.393x | -101.28% |
| 2018-12-31 | $23.87 Million | $-28.38 Million | -1.189x | -248.17% |
| 2017-12-31 | $55.00 Million | $-18.78 Million | -0.342x | +7.26% |
| 2016-12-31 | $53.34 Million | $-19.64 Million | -0.368x | +10.71% |
| 2015-12-31 | $29.33 Million | $-12.09 Million | -0.412x | +20.91% |
| 2014-12-31 | $10.58 Million | $-5.52 Million | -0.521x | -353.65% |
| 2013-12-31 | $16.97 Million | $-1.95 Million | -0.115x | -- |